According to a recent Form 13F filing with the Securities and Exchange Commission (SEC), Venture Visionary Partners LLC has reduced its position in shares of InMode Ltd. by 17.6% during the second quarter. The healthcare company’s stock saw a decrease of 12,710 shares, resulting in Venture Visionary Partners LLC owning 59,695 shares after the transaction. As of its most recent SEC filing, the value of InMode shares held by Venture Visionary Partners LLC amounted to approximately $2,230,000.
InMode Ltd. is involved in the design, development, manufacturing, and marketing of minimally invasive aesthetic medical products. These products are based on the company’s proprietary technologies known as radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency. The company operates both in the United States and internationally.
The range of minimally invasive aesthetic medical products offered by InMode includes various procedures such as liposuction with simultaneous skin tightening, body and face contouring, ablative skin rejuvenation treatments, as well as applications in women’s health conditions and procedures.
This recent trimming of their position by Venture Visionary Partners LLC may indicate a shift in their investment strategy or outlook on InMode Ltd.’s performance. While it is unclear what motivated this decision, it suggests that Venture Visionary Partners LLC may have reassessed the potential growth prospects or financial outlook for InMode.
Investors and market participants closely follow filings such as Form 13F to gain insights into institutional investors’ positions and movements within various companies. These filings provide valuable information about investor sentiment and can help shape opinions regarding future market trends.
It is important to note that this article is based on information available as of September 22, 2023. Changes in position holdings or other developments since that date may impact the current state of affairs regarding Venture Visionary Partners LLC’s position in InMode Ltd.
However, as with any investment decision, it is crucial for individuals to conduct thorough research and analysis before formulating their own opinions. Market conditions and the performance of specific companies can be influenced by numerous factors and are subject to change over time.
Disclaimer: The information in this article should not be considered as financial advice. It is recommended to seek professional guidance or conduct independent research before making any investment decisions.
[bs_slider_forecast ticker=”SAFE”]
InMode Ltd. Attracts Attention from Hedge Funds and Analysts, Positioned for Growth in Medical Aesthetics
September 22, 2023 – InMode Ltd. (NASDAQ: INMD), a healthcare company specializing in medical aesthetics and technology, has recently caught the attention of several hedge funds and financial institutions. This surge in interest comes as no surprise given its impressive performance in the market.
CIBC Private Wealth Group LLC made headlines during the fourth quarter when it acquired a new position in InMode shares valued at approximately $234,000. Similarly, Mackenzie Financial Corp joined the ranks during the first quarter, purchasing shares worth about $2,712,000. AlphaCentric Advisors LLC increased its position by 170.0% during the same period, now owning 27,000 shares valued at $863,000 after purchasing an additional 17,000 shares.
ExodusPoint Capital Management LP also recognized InMode’s potential and acquired a new position in the company’s shares during the fourth quarter for an estimated value of $1,635,000. Additionally, SG Americas Securities LLC entered the mix during the first quarter with a new position valued at approximately $283,000.
These moves from institutional investors have resulted in InMode seeing an ownership stake of 65.49% from these entities combined. It is clear that industry experts and financial professionals view InMode as a lucrative investment opportunity.
In addition to attracting institutional attention, InMode has also received positive ratings from research analysts. Robert W. Baird upped their price objective on InMode shares from $53.00 to $61.00 and gave the company an “outperform” rating in their research report released on Friday, July 28th.
Canaccord Genuity Group also expressed optimism for InMode’s future growth by increasing their price target from $47.00 to $55.00 and maintaining a “buy” rating in their report published on July 28th as well.
Barclays joined this chorus of optimism by raising their price target from $47.00 to $54.00 and giving the stock an “overweight” rating in their research report on Tuesday, August 1st. This consensus of endorsements positions InMode as a potentially attractive investment option with great upside potential.
The stock has remained resilient, with INMD opening at $32.25 on Friday. It is important to note that while InMode’s 12-month low stands at $26.10, its 12-month high is a significant $48.25.
With a market capitalization of approximately $2.68 billion and a PE ratio of 15.07, InMode demonstrates stability and strong financials in the healthcare sector. Its beta of 2.11 indicates higher volatility compared to the broader market average.
InMode released its quarterly earnings results on Thursday, July 27th, impressively reporting earnings per share (EPS) of $0.65 for the quarter, meeting analyst expectations exactly. The firm also recorded revenue of $136.08 million during this period, slightly surpassing predictions of $135.80 million.
This performance showcases InMode’s robust net margin of 36.77% and an exceptional return on equity ratio at 35.03%. These figures highlight the company’s ability to generate substantial profits for its investors.
Analysts project that InMode Ltd.’s EPS for the current year will be around $2.45 based on their average estimations.
In conclusion, it is evident that both institutional investors and research analysts have recognized InMode’s potential for growth within the healthcare sector and medical aesthetics industry specifically. With an expanding market share among hedge funds and positive ratings from expert opinions, InMode remains an enticing investment option for those seeking long-term gain in this ever-evolving field.
